- Adult
- Removed from U.S. market in 2020 due to NDMA contaminant (see adverse effects below)
- Bolus IV Dosing: 50 mg IV every 6 to 8 hours
- Continuous IV Dosing: 6.25 mg/hour IV
- Oral Dosing: 150 mg orally twice daily
- Child (15 mg/ml oral syrup)
- Removed from U.S. market in 2020 due to NDMA contaminant (see adverse effects below)
- Age <16 years old
- Dose: 5-10 mg/kg/day (max 300 mg) divided every 12 hours
- Adult dosing for over age 16 years old
- Dose: 150 mg twice daily
-
Creatinine Clearance <50 ml/min
- Give at half dose
- See H2 Blocker
- Ranitidine (Zantac) was removed from U.S. market in 2020 due to NDMA contaminant
- NDMA has been associated with several cancers
- NDMA was found both as a manufacturing contaminant
- NDMA also appears to form in vivo with Ranitidine use
- Resulted in the complete withdrawal of Ranitidine from U.S. market
- In-vivo NDMA formation does not appear to occur with other H2 Blockers
- FDA Recall Information
- https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine
- IV Ranitidine associated adverse effects
- Alanine Aminotransferase (ALT) increase
- Associated with prolonged (>5 days), high dose IV use
- Bradycardia
- Associated with rapid IV administration
-
Antacids
- Take Cimetidine at least 1-2 hours before or after Antacid medications
- Decreases absorption of other medications
- Ketoconazole
- Itraconazole
-
Warfarin
- May affect drug levels
- Pregnancy Category B
- Unknown safety in Lactation
loading